Metformin isn’t magic.
But for some people it looks dangerously close.
A 2025 study suggests this common type 2 diabetes drug could significantly boost the odds of women reaching exceptional longevity. Specifically the grand age of 90.
The numbers are stark. Women on metformin had a 30% lower risk of dying before 90 compared to those on sulfonylureas another standard diabetes medication.
How?
Scientists aren’t entirely sure yet. They call metformin a gerotherapeutic. That means it targets multiple biological pathways associated with aging. It limits DNA damage. It promotes genes linked to long life. It might even put brakes on brain wear-and-tear and reduce the severity of long COVID.
“Metformin initiation increased exceptional longevity compared to sulfonylurea initiation.”
Simple as that. Or as simple as observational data allows.
The US and German researchers dug into records of 438 postmenopausal women from a long-term American study. Half took metformin. Half took sulfonylurea. None of this was randomized. Doctors chose the treatment.
That’s a caveat. Big asterisk on the results.
You can’t prove cause and effect here. No placebo group. No random assignment. And the sample size? It’s okay but not huge.
Then again traditional randomized controlled trials (RCTs) rarely last 15 years.
This study tracked participants for an average of 14 to 15 year stretch. From midlife to deep old age. You just can’t do that with typical clinical trial budgets or patience.
“A key advantage … was the long follow-up period … not feasible in typical randomized controlled trials.”
So what are we supposed to take from this?
Maybe nothing direct if you’re a young guy wanting a life extension hack.
The researchers were blunt. Women with type 2 diabetes carry higher cardiometabolic risks than men. They face higher mortality risks generally. So results might not translate to men. Or younger folks. At all.
Why do we keep chasing this?
Because the population is graying faster than infrastructure can handle it.
The “geroscience hypothesis” posits that biological aging isn’t fixed. It’s malleable. If you slow the underlying aging process you delay the onset of multiple diseases at once. Not just cancer or heart disease. But the cluster. The whole bundle of decline.
This study points toward a potential tool in that kit.
But it’s not a prescription for longevity yet. It’s a hint.
We’ll need more trials. Better designed ones. Until then the data sits there intriguingly specific and slightly inconvenient.
One in three. That’s the gap.
Does metformin truly rewrite the clock or just help people survive it better?
Nobody knows yet.
The research has been published in the Journal of Gerontology: Medical Sciences.
